FSD Pharma (NASDAQ: HUGE) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it compare to its peers? We will compare FSD Pharma to related companies based on the strength of its earnings, valuation, dividends, institutional ownership, profitability, risk and analyst recommendations.

Valuation and Earnings

This table compares FSD Pharma and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
FSD Pharma $190,000.00 -$39.20 million -0.39
FSD Pharma Competitors $218.50 million -$99.79 million 1.73

FSD Pharma’s peers have higher revenue, but lower earnings than FSD Pharma. FSD Pharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares FSD Pharma and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
FSD Pharma N/A -102.69% -88.68%
FSD Pharma Competitors -163.69% -267.59% -46.37%

Analyst Ratings

This is a summary of current ratings and target prices for FSD Pharma and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FSD Pharma 0 0 1 0 3.00
FSD Pharma Competitors 136 361 413 14 2.33

As a group, “Medicinals & botanicals” companies have a potential upside of 108.41%. Given FSD Pharma’s peers higher possible upside, analysts clearly believe FSD Pharma has less favorable growth aspects than its peers.

Institutional and Insider Ownership

0.3% of FSD Pharma shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 25.8% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

FSD Pharma has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, FSD Pharma’s peers have a beta of 2.56, suggesting that their average stock price is 156% more volatile than the S&P 500.

Summary

FSD Pharma peers beat FSD Pharma on 8 of the 13 factors compared.

FSD Pharma Company Profile

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.

Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.